Equillium Stock Today

EQ Stock  USD 0.79  0.01  1.25%   

Market Performance

2 of 100


Odds Of Distress

Over 57

Equillium is selling at 0.79 as of the 21st of September 2023; that is -1.25% down since the beginning of the trading day. The stock's last reported lowest price was 0.78. Equillium has over 57 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Equillium are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of August 2023 and ending today, the 21st of September 2023. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
11th of October 2018
Health Care
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. The company has 34.57 M outstanding shares of which 514.76 K shares are currently sold short in the market by investors with about 1.57 days to cover all shorted shares. More on Equillium

Moving against Equillium Stock

-0.63AZNAstraZeneca PLC ADR Fiscal Quarter End 30th of September 2023 PairCorr
-0.44YSYS Biopharma Fiscal Quarter End 30th of September 2023 PairCorr
-0.43VBIVVBI Vaccines Fiscal Quarter End 30th of September 2023 PairCorr

Equillium Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Equillium's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Equillium or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CEO, DirectorGeoffrey Rotstein
Thematic IdeaPharmaceutical Products (view all)
Average Analyst Recommendation
Analysts covering Equillium report their recommendations after researching Equillium's financial statements, talking to executives and customers, or listening in on Equillium's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Equillium. The Equillium consensus assessment is calculated by taking the average forecast from all of the analysts covering Equillium.
Strong Buy5 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Equillium based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Equillium financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted30.8 M33.7 M
Significantly Down
Slightly volatile
Weighted Average Shares30.8 M33.7 M
Significantly Down
Slightly volatile
Current Liabilities34.6 M32 M
Significantly Up
Slightly volatile
Total Liabilities50.1 M46.5 M
Significantly Up
Slightly volatile
Gross Margin0.890.9
Fairly Down
Slightly volatile
Total Debt11.4 M10.2 M
Moderately Up
Slightly volatile
Asset Turnover0.220.22
Slightly volatile
Current Assets83 M76.7 M
Significantly Up
Slightly volatile
Total Assets84.3 M78.4 M
Significantly Up
Slightly volatile
Macroaxis Advice
The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Equillium's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Financial Strength
Equillium's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Equillium's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Equillium's financial leverage. It provides some insight into what part of Equillium's total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Equillium's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Equillium deploys its capital and how much of that capital is borrowed.
Equillium cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company reports 10.19 M of total liabilities with total debt to equity ratio (D/E) of 0.29, which may suggest the company is not taking enough advantage from financial leverage. Equillium has a current ratio of 3.9, indicating that it is in good position to pay out its debt commitments in time. Debt can assist Equillium until it has trouble settling it off, either with new capital or with free cash flow. So, Equillium's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Equillium sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Equillium to invest in growth at high rates of return. When we think about Equillium's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(9.42 Million)
Equillium (EQ) is traded on NASDAQ Exchange in USA. It is located in 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 and employs 47 people. Equillium is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a market capitalization of 27.31 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Equillium's market, we take the total number of its shares issued and multiply it by Equillium's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Equillium is active under Biotechnology sector as part of Health Care industry. The entity has 34.57 M outstanding shares of which 514.76 K shares are currently sold short in the market by investors with about 1.57 days to cover all shorted shares. Equillium reports about 57.56 M in cash with (8.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Equillium Probability Of Bankruptcy
Equillium holds a total of thirty-four million five hundred sixty-eight thousand five hundred outstanding shares. Equillium retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation

Check Equillium Ownership Details

Equillium Stock Price Odds Analysis

In regard to a normal probability distribution, the odds of Equillium jumping above the current price in 90 days from now is about 58.89%. The Equillium probability density function shows the probability of Equillium stock to fall within a particular range of prices over 90 days. Allowing for the 90-day total investment horizon Equillium has a beta of -0.4954 suggesting as returns on benchmark increase, returns on holding Equillium are expected to decrease at a much lower rate. During the bear market, however, Equillium is likely to outperform the market. Additionally, the company has an alpha of 0.1698, implying that it can generate a 0.17 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 0.79HorizonTargetOdds Above 0.79
40.89%90 days
Based on a normal probability distribution, the odds of Equillium to move above the current price in 90 days from now is about 58.89 (This Equillium probability density function shows the probability of Equillium Stock to fall within a particular range of prices over 90 days) .

Equillium Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Equillium that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Equillium's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Equillium's value.
InstituionLast TransactionTypeSharesValue
Decheng Capital Management Iii Cayman Llc2023-06-30Common Shares4.4 M3.3 M
Jpmorgan Chase Co2023-06-30Common Shares1.2 M893.5 K
Franklin Resources Inc2023-06-30Common Shares895 K671.2 K
Vanguard Group Inc2023-06-30Common Shares836.9 K627.7 K
Samsara Biocapital Llc2023-03-31Common Shares615.5 K449.3 K
Cota Capital Management Llc2023-06-30Common Shares562.3 K421.7 K
Tang Capital Management Llc2023-06-30Common Shares400 K300 K
Renaissance Technologies Llc2023-06-30Common Shares392.2 K294 K
True North Advisors Llc2022-12-31Common Shares265.4 K265.4 K
Deutsche Bank Ag2023-06-30Common Shares348.1 K261 K
Victory Capital Management Inc2023-03-31Common Shares345.9 K252.5 K
View Equillium Diagnostics

Equillium Historical Income Statement

Equillium Income Statement is one of the three primary financial statements used for reporting Equillium's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Equillium revenue and expense. Equillium Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of 09/21/2023, Interest Expense is likely to grow to about 1.1 M, while Consolidated Income is likely to drop (64.1 M). View More Fundamentals

Equillium Stock Against Markets

Picking the right benchmark for Equillium stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Equillium stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Equillium is critical whether you are bullish or bearish towards Equillium at a given time. Please also check how Equillium's historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Equillium without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pattern Recognition Now


Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Module

Equillium Corporate Directors

Equillium corporate directors refer to members of an Equillium board of directors. The board of directors generally takes responsibility for the Equillium's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Equillium's board members must vote for the resolution. The Equillium board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
John FisherIndependent DirectorProfile
Anthony TjanIndependent DirectorProfile
Marc LavineIndependent DirectorProfile
Charles McDermottIndependent DirectorProfile

How to buy Equillium Stock?

Before investing in Equillium, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Equillium. To buy Equillium stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Equillium. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Equillium stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Equillium stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Equillium stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Equillium, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Equillium Stock please use our How to Invest in Equillium guide.

Already Invested in Equillium?

The danger of trading Equillium is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Equillium is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Equillium. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Equillium is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Equillium. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Equillium Stock, please use our How to Invest in Equillium guide. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Equillium Stock analysis

When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Bond Directory
Find actively traded corporate debentures issued by US companies
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Is Equillium's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Equillium. If investors know Equillium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Equillium listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Return On Assets
Return On Equity
The market value of Equillium is measured differently than its book value, which is the value of Equillium that is recorded on the company's balance sheet. Investors also form their own opinion of Equillium's value that differs from its market value or its book value, called intrinsic value, which is Equillium's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Equillium's market value can be influenced by many factors that don't directly affect Equillium's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Equillium's value and its price as these two are different measures arrived at by different means. Investors typically determine if Equillium is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Equillium's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.